Report Store Get Proposal

Home Blog Pharmaceutical 2

Pharmaceutical

pharma-news-for-novo-clover-novartis

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Novo Nordisk’s STEP Young Phase 3 Results Highlight Semaglutide’s Potential in Pediatric Obesity; Clover Reports Positive Phase 2 Clinical Findings for RSV + hMPV ± PIV3 Vaccine Candidates; Novartis Reveals Topline Results From Phase III Lp(a)HORIZON Trial of Pelacarsen; US Approves Etcamah Plus CDK4/6 Inhibitor for 1st-Line Advanced HR-Positive Breast Cancer; ZANVASTRO Wins FDA Approval as a First-of-Its-Kind Disease-Modifying Treatment for Alexander Disease

Novo Nordisk’s STEP Young Phase 3 Study Shows Semaglutide Reduced Obesity Classification in 40.4% of Children Novo Nordisk announced the initial results from the STEP Young Phase 3 trial, which evaluated once-weekly semaglutide in combination with lifestyle modifications, including a reduced-calorie diet and increased physical activity, in children aged 6 to under 12 years living with obesity. The study addresses a growing health concern in this age group, where treatment options supported by clinical evidence and regulatory approval remain limited when lifestyle interventions alone are insufficient. At the start of the study, more than 85% of participants had c...

Explore More...

t-cell-malignancies-treatment-space

T-Cell Malignancies: The Evolving Treatment Landscape and the Race for Market Leadership

pharma-news-for-astrazeneca-argenx-bristol-myers-squibb

AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC; argenx Announces Favorable Topline Results from Phase 3 ALKIVIA Study of Efgartigimod; Bristol Myers Squibb’s ZENBEXUS Receives U.S. FDA Accelerated Approval in Combination with Daratumumab and Dexamethasone for Multiple Myeloma; Zealand Pharma Secures USD 100 Million in Royalty Financing Through Agreement with Royalty Pharma for Rusfertide; PTC Advances Rare Disease Strategy with Acquisition of ST-920 Fabry Disease Program

tyk2-inhibitor-for-autoimmune-disease

TYK2 Inhibitors: The Competitive Race Fueling the Next Generation of Autoimmune Therapies

tudriqev-approval-for-melanoma

Replimune Strengthens Oncology Portfolio With TUDRIQEV Approval

pharma-news-for-sobi-transthera-sciences-replimune

Sobi Partners with Innate Pharma to License Lacutamab for T-Cell Lymphoma; Yochanra Makes Global Debut in China as First Innovative Drug Designed to Overcome FGFR Inhibitor Resistance; Replimune Secures FDA Accelerated Approval for TUDRIQEV Plus Nivolumab in Advanced Cutaneous Melanoma; FDA Accepts Supplemental Biologics License Application for ENFLONSIA to Broaden RSV Indication in Young Children; Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals

benlysta-vs-gazyva

BENLYSTA vs GAZYVA: Who Wins the Battle for Lupus Nephritis Treatment?

impact-of-oral-pcsk9-inhibitors

The Emergence of Oral PCSK9 Inhibitors: A Transformative Innovation in Lipid Management

rise-of-intratumoral-cancer-therapy

Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer

pharma-news-for-astrazeneca-novartis-abbvie

EU Approves Datroway for First-Line Metastatic TNBC; FDA Broadens Pluvicto’s Reach with Approval in PSMA+ mHSPC; AbbVie Announces EU Authorization of RINVOQ for Severe Alopecia Areata; Novo Nordisk Announces Latest Developments from the ZEUS Phase III Trial; Replimune Secures Positive FDA Advisory Committee Vote for RP1 in Advanced Melanoma

protacs-treatment-landscape

PROTACs: An Emerging Drug Modality with Multiple Oncology Approvals Expected in the Coming Years

simtriyo-approval-for-adhd

Otsuka’s SIMTRIYO Approval Opens Up a Brand-New ADHD Drug Class

kras-inhibitors-beyond-g12c

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

pharma-news-for-astrazeneca-argenx-otsuka

Ultomiris Phase III Trial Update Highlights Progress in Post-Transplant TMA; argenx Acquires Forte Biosciences; Otsuka’s SIMTRIYO Receives FDA Nod as a First-in-Class ADHD Treatment; Outlook Therapeutics Secures FDA Approval for LYTENAVA to Treat Wet AMD; Merck Reveals Future Access Strategy for Once-Monthly Oral HIV Prevention Therapy Alimatravir

pd-1-inhibitors-by-companies

PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?

aβ-protein-inhibitors-in-alzheimers-disease

Aβ-Protein Inhibitors in Alzheimer’s Disease: The Amyloid-Busting Arsenal Redefining Care

Lupus Nephritis Treatment Market Outlook and Emerging Therapies

Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly